Artificial intelligence learns to recognize subtle biochemical features of γ-secretase substrates. Screening potential transmembrane proteins identifies 250 substrates, including 160 novel ones. These ...

With aging, fibrinogen transcytosed via caveolin-1 into the perivascular space, exacerbating Aβ buildup. Elevated fibrinogen disrupted aquaporin-4 function. Depleting fibrinogen rescued CAA, ...

Eight months after Eli Lilly reported that a more gradual titration for donanemab nearly halved the risk of ARIA-E, the U.S. Food and Drug Administration has given the modification the green light.

Why do some people age rapidly while others maintain their health well into their 80s and 90s? A new study suggests that maintaining “youthful” organs may be key. Scientists led by Tony Wyss-Coray at ...

Discover a comprehensive list of brain banks worldwide, facilitating Alzheimer's and Parkinson's research on Alzforum.

Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 ...

Scientists from academia, pharmaceutical companies, and healthcare analysis firms reached no consensus on a threshold for meaningfulness, but broadly agreed that meaningfulness should be determined ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

Sasner sat down with Alzforum to go over what models are available now, which ones are coming, and how they could be used. The new mouse lines are the product of two different initiatives: NIA’s Model ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...

The top-line results last September from Eisai’s Phase 3 trial of the anti-amyloid antibody lecanemab galvanized the field, but scientists said they needed to see the data before passing judgement.

Earlier this year, a high-profile Science paper caused a stir with its claim that the brain has a fourth, previously unrecognized, meningeal membrane. Dubbed SLYM and containing Prox1+ cells, this ...